Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of bupivacaine and saline is a pharmacological preparation used primarily as a local anesthetic and as a control intervention in clinical research. Bupivacaine is a long-acting amide-type local anesthetic that functions by binding to the intracellular portion of voltage-gated sodium channels. This binding stabilizes the neuronal membrane and inhibits the ionic fluxes required for the initiation and conduction of nerve impulses, effectively blocking pain signals. In the context of clinical trials conducted by Tanta University, this specific formulation (typically 29 ml of 0.25% bupivacaine mixed with 1 ml of 0.9% saline) is administered via regional techniques such as the external oblique intercostal plane (EOIP) block to manage post-thoracotomy pain. Saline serves as an isotonic vehicle and diluent, often used to match the volume of an active adjuvant being tested in the experimental arm of a study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + saline.